This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes; obesity	Solute carrier family 13 sodium-dependent citrate transporter member 5 (SLC13A5)	<p>Mouse studies suggest inhibiting SLC13A5 could help treat obesity and type 2 diabetes. In mice fed a high-fat diet, Slc13a5 deficiency led to lower body weight, greater lean body mass and better hepatic insulin responsiveness than Slc13a5 expression. Next steps could include studying SLC13A5 deficiency in a mouse model of diabetes.</p> <p>SciBX 4(32); doi:10.1038/scibx.2011.910 Published online Aug. 18, 2011</p>	Patent and licensing status undisclosed	<p>Birkenfeld, A.L. <i>et al. Cell Metab.</i>; published online Aug. 3, 2011; doi:10.1016/j.cmet.2011.06.009</p> <p>Contact: Gerald I. Shulman, Yale School of Medicine, New Haven, Conn. e-mail: gerald.shulman@yale.edu</p>